| Prostatic specific antigen for prostate cancer detection. | |
| | |
MedLine Citation:
|
PMID: 19860930 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Prostate-specific antigen (PSA) has been used for prostate cancer detection since 1994. PSA testing has revolutionized our ability to diagnose, treat, and follow-up patients. In the last two decades, PSA screening has led to a substantial increase in the incidence of prostate cancer (PC). This increased detection caused the incidence of advanced-stage disease to decrease at a dramatic rate, and most newly diagnosed PC today are localized tumors with a high probability of cure. PSA screening is associated with a 75% reduction in the proportion of men who now present with metastatic disease and a 32.5% reduction in the age-adjusted prostate cancer mortality rate through 2003. Although PSA is not a perfect marker, PSA testing has limited specificity for prostate cancer detection, and its appropriate clinical application remains a topic of debate. Due to its widespread use and increased over-detection, the result has been the occurrence of over-treatment of indolent cancers. Accordingly, several variations as regards PSA measurement have emerged as useful adjuncts for prostate cancer screening. These procedures take into consideration additional factors, such as the proportion of different PSA isoforms (free PSA, complexed PSA, pro-PSA and B PSA), the prostate volume (PSA density), and the rate of change in PSA levels over time (PSA velocity or PSA doubling time). The history and evidence underlying each of these parameters are reviewed in the following article. |
| | |
Authors:
|
Lucas Nogueira; Renato Corradi; James A Eastham |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: International braz j urol : official journal of the Brazilian Society of Urology Volume: 35 ISSN: 1677-6119 ISO Abbreviation: Int Braz J Urol Publication Date: 2009 Sep-Oct |
Date Detail:
|
Created Date: 2009-10-28 Completed Date: 2010-12-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101158091 Medline TA: Int Braz J Urol Country: Brazil |
Other Details:
|
Languages: eng Pagination: 521-9; discussion 530-2 Citation Subset: IM |
Affiliation:
|
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 , USA. nogueirl@mskcc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Humans Male Prostate-Specific Antigen / blood* Prostatic Neoplasms / blood, diagnosis* Reference Values Sensitivity and Specificity |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New trends in minimally invasive urological surgery.
Next Document: Sonographic detection of renal and ureteral stones. Value of the twinkling sign.